The interest in research and development for additive manufacturing (AM) processes has grown significantly over the last years and attracts both industry and academia alike. Among the available AM technologies, stereolithography (SLA) is one of the most discussed, researched, and employed. On the other hand, being based on thermoset resins, all the limitations of this typology of materials still apply, limiting the range of applications of this highly versatile process. To overcome these limitations, especially brittleness, this research analyzes the effects of Tungsten (W) micro-size (average size 1 μm) particles reinforcement on a methacrylate base material. First, the manufacturing process for creating the W-reinforced methacrylate material is presented and investigated to define the effect of pre- and post-processing operations on the quality of the pre-cured solution considering 4% and 10% wt. W particles concentrations. Afterward, tensile, compressive, and impact specimens were manufactured with both concentrations and compared with the experimental results from clear (unfilled) resin-based specimens used as the benchmark. The addition of tungsten particles showed a strong improvement in the impact strength of the methacrylate base material, quantified in 28% for the 4% and 55% for the 10% wt., respectively, although at the expense of a slight reduction in elastic and yield properties on average -12%. Furthermore, using Scanning Electron Microscope (SEM) analyses, the particle-matrix interaction was investigated, showing the interaction between the polymer matrix and the reinforcement and the mechanism by which the impact resistance is enhanced.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10747924 | PMC |
http://dx.doi.org/10.3390/polym15244728 | DOI Listing |
Bone Marrow Transplant
January 2025
Université de Franche-Comté, EFS, INSERM, UMR RIGHT, F-, 25000, Besançon, France.
The accessibility of CAR-T cells in centralized production models faces significant challenges, primarily stemming from logistical complexities and prohibitive costs. However, European Regulation EC No. 1394/2007 introduced a pivotal provision known as the hospital exemption.
View Article and Find Full Text PDFSci Rep
January 2025
Refined Imaging LLC, Baton Rouge, LA, 70810, USA.
This study describes procedures for embedding digital information into additively manufactured components as well as procedures for readout and tensile testing. Embedded digital codes were printed inside ASTM E8/E8M dumbbells using Direct Metal Laser Melting (DMLS) with an EOS M290 printer. The codes were configured as either ellipsoids or prolate spheroids in patterns given by the Cantor dust fractal.
View Article and Find Full Text PDFInt J Pharm
January 2025
Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain; FABRX Artificial Intelligence, Carretera de Escairón, 14, Currelos (O Saviñao) CP 27543, Spain; FABRX Ltd., Henwood House, Henwood, Ashford, Kent TN24 8DH, UK; Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK. Electronic address:
Compounding medications in pharmacies is a common practice for patients with prescriptions that are not available commercially, but it is a laborious and error-prone task. The incorporation of emerging technologies to prepare personalised medication, such as 3D printing, has been delayed in smaller pharmacies due to concerns about potential workflow disruptions and learning curves associated with novel technologies. This study examines the use in a community pharmacy of a pharmaceutical 3D printer to auto-fill capsules and blisters using semisolid extrusion, incorporating an integrated quality control system.
View Article and Find Full Text PDFJ Chromatogr B Analyt Technol Biomed Life Sci
January 2025
Resorcinol is a widespread substance used in a large variety of manufacturing industries, including cosmetics, with endocrine-disrupting activity on the thyroid function. The aim of the present study was to develop and validate a sensitive, selective and robust method to quantify resorcinol in urine and thereby assess hairdressers' occupational exposure. As resorcinol is mainly excreted in urine as glucuronide or sulfate forms, the first step consisted in hydrolyzing urine samples with a β-glucuronidase-arylsulfatase enzyme for 16 h.
View Article and Find Full Text PDFAm J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!